Project Grant R43CA257324

Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...

Federal Grant Award Summary Seak Therapeutics, LLC received a $399,981 Small Business Technology Transfer (STTR) Phase 1 award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period of September 19, 2025 through August 31, 2026. The award supports preclinical development and de-risking of SEAK193, a novel antimitotic agent designed to treat breast cancer brain metastases (BCBMs) and potentially other brain malignancies. The project focuses...

Federal Project Grant Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The award funds the development of multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype with poor prognosis, particularly in adult patients over 40 years of age where overall...

Federal Grant Award Summary The National Cancer Institute awarded The Children's Hospital of Philadelphia $457,683 under the Cancer Treatment Research program (CFDA 93.395) for a Project Grant effective April 1, 2026, through March 31, 2028. The award supports research focused on enhancing drug delivery mechanisms to treat high-risk neuroblastoma, the most common and deadliest solid tumor in childhood. The project will develop and optimize a macromolecular prodrug-based delivery system utilizing...

Federal Project Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $470,759 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2027. The award supports the development of PA-Regulator Controlled, JMJD6 Reprogrammed GPC3-CAR T Cells for patients with hepatocellular carcinoma. The research addresses a critical...

Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $456,414 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2025, through April 30, 2030. This award supports the clinical development and evaluation of B7-H3 Chimeric Antigen Receptor (CAR) T cell therapy for children and young adults with Diffuse Intrinsic Pontine Glioma (DIPG), a fatal...

Grant Award Summary The University of Pennsylvania received a $695,205 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct early-phase clinical trials of 211-astatine-meta-astatobenzylguanidine (211At-MABG) for treating neuroblastoma in children and advanced neuroendocrine cancers in adults. The award period runs from June 1, 2025, through May 31, 2030. The research addresses limitations of existing treatments,...

The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...

The Department of Defense's Defense Health Agency awarded a $3,188,604 Project Grant titled "USE OF HIGH-THROUGHPUT SEQUENCING OF THE IMMUNOGLOBULIN LOCI FOR REFINED RISK STRATIFICATION IN PEDIATRIC B-ALL" to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. This grant, funded through the Military Medical Research and Development (CFDA 12.420) program, supports biomedical research related to military medicine, with a focus on cancer, neurological...

This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $624,000.00 to the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to conduct "COMPREHENSIVE IN VIVO PHENOTYPING OF FUSION-DRIVEN PEDIATRIC RHABDOMYOSARCOMAS". This 2-year research project aims to advance the understanding and treatment of pediatric rhabdomyosarcoma, an aggressive form of soft tissue cancer, by investigating the...